Medtronic (MDT) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Medtronic plc (MDT) insider buying and selling: 2 purchases, 8 sales
70 Form 4 Table I transactions filed with the SEC by Medtronic plc insiders between 2025-08-25 and 2026-10-21 (15-month history): 2 open-market purchases and 8 sales, plus 60 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $5.1M by Kiil Harry Skip on 2026-02-19.
Medtronic insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Medtronic insiders filed 7 sales worth $14.7M on the open market, and no purchases.
The biggest seller was Kiil Harry Skip (EVP & President Cardiovascular): $5.6M in 3 sales, out of 5 different sellers.
The largest trade of the period was a sale of $5.1M on Feb 19, 2026, by Kiil Harry Skip (EVP & President Cardiovascular). Form 4 on sec.gov (0001708062-26-000002).
Of the 7 sales, 3 (43%, $6.0M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other 4 do not.
The last three months show 3 sales, against 2 in the three before. The latest sale from Oct 15, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Medtronic has more sales than 25 of the other 58, ranks 30 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
The 2 open-market purchases first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 70 MDT trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2025-08-22 | 2025-08-25 | Jellison William R | Director | $232k | P — Open-market purchase | SEC |
| 2025-08-25 | 2025-08-25 | Jellison William R | Director | $231k | P — Open-market purchaseForm 4 footnoteF1 Shares are held in joint account with spouse. | SEC |
| 2026-02-19 | 2026-02-26 | Kiil Harry Skip | EVP & President Cardiovascular | $5.1M | S — Open-market saleForm 4 footnoteF2 The price reported is a weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $97.60 to $97.775. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder upon request. | SEC |
| 2026-10-15 | 2026-10-16 | Martha Geoffrey | Chairman and CEO | $4.8M | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2025-11-19 | 2025-11-21 | Smith Gregory L | EVP Global Ops & Supply Chain | $3.1M | S — Open-market saleForm 4 footnoteF1 Includes 323 shares acquired through dividend reinvestment and 96 shares acquired under Medtronic's Employee Stock Ownership Plan since the last report filed by the reporting person. | SEC |
| 2026-10-15 | 2026-10-16 | Marinaro Michael | EVP, Pres MedSurg and Americas | $1.0M | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2025-09-03 | 2025-09-05 | Kiil Harry Skip | EVP & President Cardiovascular | $788k | S — Open-market sale | SEC |
| 2026-06-08 | 2026-06-09 | Kiil Harry Skip | EVP & President Cardiovascular | $337k | S — Open-market sale | SEC |
| 2026-07-08 | 2026-07-09 | Walter Matthew R. | SVP, Chief HR Officer | $258k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Includes 107 shares acquired under Medtronic's Employee Stock Ownership Plan since the last report filed by the reporting person. | SEC |
| 2026-09-16 | 2026-09-17 | Kiil Harry Skip | EVP & President Cardiovascular | $139k | S — Open-market sale | SEC |
| 2026-02-19 | 2026-02-26 | Kiil Harry Skip | EVP & President Cardiovascular | $4.6M | M — Option exerciseForm 4 footnoteF1 Includes 239 shares acquired through dividend reinvestment since the last report filed by the reporting person. | SEC |
| 2026-06-04 | 2026-06-08 | Martha Geoffrey | Chairman and CEO | $3.5M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. | SEC |
| 2026-07-31 | 2026-08-04 | Martha Geoffrey | Chairman and CEO | $1.4M | F — Tax withholding (shares surrendered for taxes)2 Form 4 footnotesF1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 980 shares acquired through dividend reinvestment since the last report filed by the reporting person. | SEC |
| 2026-06-04 | 2026-06-08 | Marinaro Michael | EVP, Pres MedSurg and Americas | $622k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. | SEC |
| 2026-06-04 | 2026-06-08 | Kiil Harry Skip | EVP & President Cardiovascular | $568k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. | SEC |
| 2026-03-03 | 2026-03-05 | Pieton Thierry | EVP & Chief Financial Officer | $288k | F — Tax withholding (shares surrendered for taxes)2 Form 4 footnotesF1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 592 shares acquired through dividend reinvestment since the last report filed by the reporting person. | SEC |
| 2026-07-31 | 2026-08-04 | Marinaro Michael | EVP, Pres MedSurg and Americas | $287k | F — Tax withholding (shares surrendered for taxes)2 Form 4 footnotesF1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 547 shares acquired through dividend reinvestment since the last report filed by the reporting person. | SEC |
| 2026-07-31 | 2026-08-04 | Kiil Harry Skip | EVP & President Cardiovascular | $262k | F — Tax withholding (shares surrendered for taxes)2 Form 4 footnotesF1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 286 shares acquired through dividend reinvestment since the last report filed by the reporting person. | SEC |
| 2026-06-04 | 2026-06-08 | Walter Matthew R. | SVP, Chief HR Officer | $237k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. | SEC |
| 2026-07-28 | 2026-07-29 | Quinn Michelle | EVP, GC and Secretary | $180k | F — Tax withholding (shares surrendered for taxes)2 Form 4 footnotesF1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 697 shares acquired through dividend reinvestment since the last report filed by the reporting person. | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Aug 25, 2025 and Oct 21, 2026, Medtronic plc open-market activity adds up to 2 purchases worth $463k and 8 sales worth $15.5M. The net balance is $15.0M on the sell side.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Medtronic plc's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| F | Tax withholding (shares surrendered for taxes) | 29 | $8.4M |
| A | Grant or award | 20 | $0 |
| S | Open-market sale | 8 | $15.5M |
| M | Option exercise | 7 | $4.6M |
| G | Gift | 3 | $0 |
| P | Open-market purchase | 2 | $463k |
| J | Other transaction (explained in the filing) | 1 | $0 |
| Total | Everything filed in the period | 70 | $29.0M |
30 of the 70 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 21 distinct people or entities have filed Medtronic plc transactions: 1 bought on the open market and 5 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Kiil Harry Skip | EVP & President Cardiovascular | 10 | — | $6.4M (4) | 2026-09-17 |
| Martha Geoffrey | Chairman and CEO | 6 | — | $4.8M (1) | 2026-10-16 |
| Smith Gregory L | EVP Global Ops & Supply Chain | 1 | — | $3.1M (1) | 2025-11-21 |
| Marinaro Michael | EVP, Pres MedSurg and Americas | 7 | — | $1.0M (1) | 2026-10-16 |
| Jellison William R | Director | 3 | $463k (2) | — | 2026-04-29 |
| Walter Matthew R. | SVP, Chief HR Officer | 6 | — | $258k (1) | 2026-08-04 |
| Blomquist Denise L. | Chief Accounting Officer | 10 | — | — | 2026-09-16 |
| Lofton Kevin E | Director | 3 | — | — | 2026-10-21 |
Shown here are the 8 who moved the most money, out of 21. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Aug 2025: 2 purchases and 0 sales, worth $463k. 7 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 2 | $463k | 0 | $0 |
| Sep 2025 | 0 | $0 | 1 | $788k |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 1 | $3.1M |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 1 | $5.1M |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 0 | $0 |
| Jun 2026 | 0 | $0 | 1 | $337k |
| Jul 2026 | 0 | $0 | 1 | $258k |
| Aug 2026 | 0 | $0 | 0 | $0 |
| Sep 2026 | 0 | $0 | 1 | $139k |
| Oct 2026 | 0 | $0 | 2 | $5.8M |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Medtronic plc (MDT) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
3 of the 8 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Medtronic's 2 open-market purchases (code P) are the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Oct 21, 2026, and a Form 4 arrives up to two business days after the trade.
14 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.